Composition containing schizophyllan and N-acetylneuraminic acid and application thereof
By combining schistosome extract with N-acetylneuraminic acid, the problem of the difficulty of single ingredients in synergistic intervention of skin aging is solved, and the synergistic anti-aging effect of promoting collagen production and reducing oxidative stress and cell damage is achieved.
Patent Information
- Application Number
- CN202511929297.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-12-19
- Publication Date
- 2026-03-10
AI Technical Summary
Existing anti-aging ingredients mostly focus on single pathway regulation, making it difficult to achieve multi-target synergistic effects, and single ingredients are difficult to synergistically intervene in the skin aging process.
Schizotypalin is compounded with N-acetylneuraminic acid in a mass ratio of 1:(0.2-8) and used in skin anti-aging compositions, supplemented with other active ingredients and media, to prepare cosmetics or pharmaceuticals.
The combination of schistosome extract and N-acetylneuraminic acid significantly promotes collagen production, reduces oxidative stress and cell damage, and enhances anti-aging effects.
Smart Images
Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] This invention belongs to the field of daily chemical technology and relates to a composition containing schistosome and N-acetylneuraminic acid and its application. Background Technology
[0002] Skin aging is a complex biological process influenced by both endogenous and exogenous factors, primarily manifested as decreased cell regeneration capacity, extracellular matrix degradation (such as collagen loss), cumulative oxidative stress damage, and decline in barrier function. Current research on anti-aging active ingredients largely focuses on single-pathway regulation, but the actual aging process involves the intertwined effects of multiple targets, making it difficult for a single ingredient to achieve synergistic intervention.
[0003] Schizotypalin, a β-glucan, has been shown to activate macrophages and enhance skin immune regulation. It can also reduce the adverse effects of inflammation and oxidative stress on cells by inhibiting inflammation-related pathways such as NF-κB and MAPK, activating the Nrf2 anti-inflammatory pathway, and rebalancing TH1 / TH17 and macrophage M1 / M2 polarization.
[0004] N-acetylneuraminic acid (Neu5Ac), a key component of cell membrane surface glycoproteins and one of the functional sugars in the human body, is located at the end of glycoproteins and glycolipids. It participates in intercellular communication and self-recognition by the immune system. It is often used as the terminal residue of glycans and is linked by α2-3 or α2-6 bonds. It significantly affects the stability, half-life and receptor binding of glycoproteins and regulates many physiological functions through sialylation modification.
[0005] Currently, there are no reports of using these two products together for skin anti-aging. Summary of the Invention This application provides a composition containing myxobin and N-acetylneuraminic acid. Experimental verification shows that the combination of myxobin and N-acetylneuraminic acid has a better effect on preventing skin cell aging than their individual use, exhibiting a synergistic anti-aging effect.
[0006] The specific technical solution of this application is as follows: A composition comprising at least schistosome and N-acetylneuraminic acid.
[0007] Furthermore, the mass ratio of schistosin to N-acetylneuraminic acid is 1:(0.2-8), for example, any mass ratio range between 1:0.2, 1:0.3, 1:0.4, 1:0.5, 1:0.6, 1:0.7, 1:0.8, 1:0.9, 1:1.0, 1:1.5, 1:2.0, 1:2.5, 1:3.0, 1:3.5, 1:4.0, 1:4.5, 1:5.0, 1:5.5, 1:6.0, 1:6.5, 1:7.0, 1:7.5, 1:8.0, preferably 1:(0.4-8), more preferably 1:(4-8).
[0008] Furthermore, the content of schistosome in the above composition is 0.015-0.07 wt%, for example, 0.015%, 0.02%, 0.025%, 0.03%, 0.035%, 0.04%, 0.045%, 0.05%, 0.055%, 0.06%, 0.065%, 0.07%, and any mass ratio range between these values.
[0009] Furthermore, the content of N-acetylneuraminic acid in the above composition is 0.03-0.085 wt%, for example, 0.03%, 0.035%, 0.04%, 0.045%, 0.05%, 0.055%, 0.06%, 0.065%, 0.07%, 0.075%, 0.08%, 0.085%, and any mass ratio range between these values.
[0010] Those skilled in the art can adjust the mass concentration of the composition according to actual needs, therefore, this application does not make specific limitations on this content.
[0011] Furthermore, as anti-aging active ingredients for the skin, schistosomes and N-acetylneuraminic acid may be included in the above composition in addition to schistosomes and N-acetylneuraminic acid, as well as other active ingredients with different effects and physiologically acceptable media.
[0012] In this application, the physiologically acceptable medium may be a suitable solvent, propellant, solubilizer, co-solvent, emulsifier, colorant, binder, disintegrant, filler, lubricant, humectant, osmotic pressure regulator, stabilizer, flow aid, flavoring agent, preservative, suspending agent, coating material, fragrance, anti-adhesion agent, binding agent, penetration enhancer, pH adjuster, buffer, plasticizer, surfactant, foaming agent, defoamer, thickener, UV filter, antioxidant, encapsulating agent, humectant, absorbent, diluent, flocculant and anti-flocculation agent, filter aid, release inhibitor, fragrance, etc.
[0013] As a solvent, such as an aqueous solvent or an oil-based solvent.
[0014] As emollients, such as squalane, isohexadecane, polydimethylsiloxane, jojoba esters, etc.
[0015] As thickeners, such as xanthan gum, polyacrylic acid compounds, cellulose compounds, bentonite, fatty alcohols, etc.
[0016] As UV filters, they include benzophenone, 4-butylmethoxydibenzoylmethane, octocrylene, ethylhexyl methoxycinnamate, ethylhexyl salicylate, phenylbenzimidazole sulfonic acid, or homosalyl ester.
[0017] As antioxidants, such as tocopherol acetate, p-hydroxyacetophenone, BHT and BHA.
[0018] As emulsifiers, such as anionic emulsifiers, cationic emulsifiers, amphoteric emulsifiers, and nonionic emulsifiers.
[0019] As fillers, such as oxides of silica, mica, kaolin, zinc and titanium from natural or synthetic sources; calcium carbonate, magnesium carbonate, magnesium bicarbonate; zinc stearate, magnesium stearate, lithium stearate, zinc laurate, magnesium myristate, etc.
[0020] As colorants, such as iron oxide, carbon black, titanium dioxide, zinc oxide, carmine, carotene, chlorophyll, etc.
[0021] As preservatives, such as phenoxyethanol, benzyl alcohol, benzoic acid, sorbic acid, imidazolidinyl urea, etc.
[0022] As a fragrance ingredient, it can be used in various ways, such as citronellol and tricyclodecenyl acetate.
[0023] In a preferred embodiment, the solvent is water.
[0024] In this application, the active ingredients with other effects include active ingredients with moisturizing effects, active ingredients with anti-aging effects, active ingredients with whitening effects, etc.
[0025] Active ingredients that provide moisturizing benefits include mannitol, sodium hyaluronate, lactic acid, glycerin, allantoin, and propylene glycol.
[0026] Active ingredients that have anti-aging effects include retinol and its derivatives, peptides, phytosterols, milk thistle extract, etc.
[0027] Active ingredients that have skin-whitening effects include niacinamide, arbutin, phenylethyl resorcinol, ascorbic acid and its derivatives.
[0028] Furthermore, the compositions of this application can be prepared by common methods, wherein one or more diluents or carriers may be added. The compositions of this application can be prepared into any formulation commonly prepared in this field. For example, it can be formulated into creams, lotions, emulsions, masks, foundations, medical devices, hair cosmetics, and other formulations. Specifically, skin lotions, skin softeners, hyaluronic acid injections, skin toners, astringents, lotions, moisturizing lotions, nourishing lotions, massage creams, nourishing creams, moisturizing creams, hand creams, foundations, serums, nourishing essences, masks, soaps, cleansing foams, cleansing milks, cleansing creams, lotions, or shower gels.
[0029] Furthermore, the "composition" only needs to achieve the effects described in this application, and the "composition" includes, but is not limited to, the simultaneous or sequential use of each component. "Simultaneous use" includes using them together in the same formulation or separately in different formulations. "Sequential use" includes using them sequentially in different formulations, and there are no restrictions on the order of use. For example, when the composition contains schistosome extract, N-acetylneuraminic acid, and water, these three can be directly mixed and stirred until completely dissolved to obtain the composition. There are no special requirements for the mixing order of the components; they can be mixed in pairs or all three together. Schistosome extract and N-acetylneuraminic acid can be prepared as an aqueous solution first, or added directly in pure form. To accelerate and promote the dissolution of each component, auxiliary methods such as stirring, heating, and ultrasound can be used.
[0030] This application also provides the use of the above-mentioned composition containing schistosome and N-acetylneuraminic acid in the preparation of products that promote collagen production.
[0031] Furthermore, the collagen is preferably type I collagen.
[0032] This application also provides the use of the above-mentioned composition containing schistosome and N-acetylneuraminic acid in the preparation of products that reduce oxidative stress.
[0033] This application also provides the use of the above-mentioned composition containing schistosome and N-acetylneuraminic acid in the preparation of products that reduce cell damage.
[0034] This application also provides the use of the above-mentioned composition containing schistosome and N-acetylneuraminic acid in the preparation of anti-skin aging products.
[0035] Furthermore, the products that promote collagen production, reduce oxidative stress, reduce cell damage, or combat skin aging can be cosmetics. Cosmetics can be specific types such as face creams, face masks, eye creams, neck creams, hand creams, body lotions, moisturizers, serums, toners, shampoos, conditioners, scalp treatments, shower gels, facial cleansers, mouthwash, or toothpaste.
[0036] Furthermore, the product that promotes collagen production, reduces oxidative stress, reduces cell damage, or combats skin aging can be a pharmaceutical product. Depending on the dosage form requirements, the pharmaceutical product may include acceptable excipients required to meet the dosage form requirements. Examples of acceptable excipients include solvents, diluents, excipients, buffers, fillers, binders, disintegrants, preservatives, lubricants, odorants, flavorings, and sweeteners. Beneficial effects: This application is the first to demonstrate that schistosome and N-acetylneuraminic acid have synergistic skin care effects, especially the physiological function of synergistically promoting collagen synthesis and anti-aging; the combination of schistosome and N-acetylneuraminic acid shows a synergistic effect in promoting collagen production and anti-aging. Detailed Implementation
[0037] The present invention will be further described below with reference to embodiments. It should be understood that the embodiments are only used to further illustrate and explain the present invention, and are not intended to limit the present invention.
[0038] Unless otherwise defined, the technical and scientific terms used in this specification have the same meaning as commonly understood by one of ordinary skill in the art. While similar or identical methods and materials may be applied in experimental or practical applications, materials and methods are described herein. In case of conflict, the definitions in this specification shall prevail. Furthermore, materials, methods, and examples are for illustrative purposes only and are not restrictive.
[0039] Unless otherwise specified, all concentrations in the following examples and comparative examples are mass percentages.
[0040] The materials and reagents used in the following examples and comparative examples are shown in the table below.
[0041] The equipment used in the following embodiments and comparative examples is shown in the table below.
[0042] Example 1 0.07g of schistosome was slowly added to 99.9g of deionized water, and the mixture was kept in a water bath at 45°C and stirred for 20 minutes until a clear and homogeneous solution was formed. Then the mixture was cooled to room temperature and 0.03g of N-acetylneuraminic acid was added. The mixture was stirred and dispersed evenly to obtain the composition.
[0043] Example 2 0.03g of schistosome was slowly added to 99.9g of deionized water, and the mixture was kept in a water bath at 45°C and stirred for 20 minutes until a clear and homogeneous solution was formed. Then, the mixture was cooled to room temperature and 0.07g of N-acetylneuraminic acid was added. The mixture was stirred and dispersed evenly to obtain the composition.
[0044] Example 3 0.02 g of schistosome was slowly added to 99.9 g of deionized water, and the mixture was kept in a water bath at 45 °C and stirred for 20 min until a clear and homogeneous solution was formed. Then, the mixture was cooled to room temperature and 0.08 g of N-acetylneuraminic acid was added. The mixture was stirred and dispersed evenly to obtain the composition.
[0045] Example 4 0.015g of schistosome was slowly added to 99.9g of deionized water, and the mixture was kept in a water bath at 45°C and stirred for 20 minutes until a clear and homogeneous solution was formed. Then, the mixture was cooled to room temperature and 0.085g of N-acetylneuraminic acid was added. The mixture was stirred and dispersed evenly to obtain the composition.
[0046] Example 5 0.0115g of schistosome was slowly added to 99.9g of deionized water, and the mixture was kept in a water bath at 45°C and stirred for 20 minutes until a clear and homogeneous solution was formed. Then, the mixture was cooled to room temperature and 0.0885g of N-acetylneuraminic acid was added. The mixture was stirred and dispersed evenly to obtain the composition.
[0047] Example 6 0.015g of schistosome was slowly added to 99.95g of deionized water, and the mixture was kept in a water bath at 45°C and stirred for 20 minutes until a clear and homogeneous solution was formed. Then, the mixture was cooled to room temperature and 0.035g of N-acetylneuraminic acid was added. The mixture was stirred and dispersed evenly to obtain the composition.
[0048] Comparative Example 1 Slowly add 0.1g of schistosome to 99.9g of deionized water, maintain the water bath at 45℃, and stir for 20 minutes until a clear and homogeneous solution is formed.
[0049] Comparative Example 2 0.01g of schistosome was slowly added to 99.9g of deionized water, and the mixture was kept in a water bath at 45°C and stirred for 20 minutes until a clear and homogeneous solution was formed. Then, the mixture was cooled to room temperature and 0.09g of N-acetylneuraminic acid was added. The mixture was stirred and dispersed evenly to obtain the composition.
[0050] Comparative Example 3 0.0875g of schistosome was slowly added to 99.9g of deionized water, and the mixture was kept in a water bath at 45°C and stirred for 20 minutes until a clear and homogeneous solution was formed. Then, the mixture was cooled to room temperature and 0.0125g of N-acetylneuraminic acid was added. The mixture was stirred and dispersed evenly to obtain the composition.
[0051] Comparative Example 4 Slowly add 0.1g of N-acetylneuraminic acid to 99.9g of deionized water and stir to disperse evenly.
[0052] Comparative Example 5 Slowly add 0.05g of schistosome to 99.95g of deionized water, maintain the water bath at 45℃, and stir for 20 minutes until a clear and homogeneous solution is formed.
[0053] Comparative Example 6 Slowly add 0.05g of N-acetylneuraminic acid to 99.95g of deionized water and stir to disperse evenly.
[0054] Experimental Example: Improving the Effects of H2O2 Pressure on Senescent Fibroblasts The specific steps are as follows: 1) Cell seeding: at 1×10 5 Human dermal fibroblasts were seeded into 24-well plates at a seeding density of cells / well and incubated overnight in an incubator (37°C, 5% CO2) using 90% low-glucose DMEM medium with 10% fetal bovine serum.
[0055] 2) Induction and Drug Administration: When the cell deposition rate in the 24-well plates reached 40%–60%, 10× H2O2 working solution (i.e., 0.005% H2O2 aqueous solution) was added to the wells of the experimental group, positive control group, and negative control group to induce cell induction. No H2O2 was added to the blank control group. The wells were shaken left and right to mix the drug. Then, the samples from the examples and comparative examples were added to the experimental group, VC solution was added to the positive control group, and no samples were added to the blank control group and negative control group. The final H2O2 concentration was maintained at 0.0005%, and each group had 3 replicates. After sample addition, the wells were placed in an incubator (37℃, 5% CO2) for 24 h of incubation.
[0056] 3) Sample collection: After incubation, collect the cell culture supernatant into EP tubes (Note: Determine the amount of sample to be collected according to the detection indicators). After collection, freeze the sample in a -80℃ freezer.
[0057] 4) Cytokine content detection: The content of human type I collagen (COL I) was detected by ELISA according to the instructions of the kit, and the content of lipid oxides (MDA) was detected by lipid oxidation (MDA) assay kit. The ratio of COL I content in each group to that in the negative control group was used as the relative amount of COL I synthesis, and the ratio of MDA content in each group to that in the negative control group was used as the relative amount of MDA synthesis.
[0058] The test results are shown in Tables 1 and 2 below: Table 1 Note: The significance between test groups is expressed by letter notation. If there is only one letter in the same letter, the difference is not significant. If there are different letters in the same letter, the difference is significant.
[0059] The results in the table above show that, under the specified proportions and concentrations in the examples, the composition effectively promotes the synthesis of COLⅠ, with a significantly higher synthesis amount than that of single components and comparative examples 2-3 with other ratios, as well as the negative control. This indicates that, within a specific ratio range, the synergistic effect of schistosin and N-acetylneuraminic acid can effectively promote collagen synthesis and exert anti-aging physiological functions.
[0060] Table 2 Note: The significance between test groups is expressed by letter notation. If there is only one letter in the same letter, the difference is not significant. If there are different letters in the same letter, the difference is significant.
[0061] MDA (malondialdehyde) is a key end product of lipid peroxidation in vivo. As a core indicator for assessing oxidative stress levels and cell damage, it is directly related to cell membrane damage, DNA damage, protein inactivation, and inflammation activation; higher MDA levels indicate more severe damage. The results in the table above show that the compositions of Examples 1 and 2 effectively reduced MDA synthesis, with significantly lower synthesis levels than other comparative examples and the negative control. This indicates that, within a specific ratio range, schistosomes and N-acetylneuraminic acid synergistically reduce oxidative stress levels and decrease the physiological function of cell damage.
Claims
1. A composition characterized in that, at least comprising a split protein and N-acetylneuraminic acid.
2. The composition of claim 1, wherein, The mass ratio of the split protein to the N-acetylneuraminic acid is 1: (0.2-8).
3. The composition according to any one of claims 1-2, characterized in that, The mass ratio of the split protein to the N-acetylneuraminic acid is 1: (0.4-8).
4. The composition of claim 1, wherein, The content of the split protein in the composition is 0.015-0.07 wt%.
5. The composition of claim 1, wherein, The content of the N-acetylneuraminic acid in the composition is 0.03-0.085 wt%.
6. The composition according to any one of claims 1-5, characterized in that, Also included is a medium acceptable to human physiology.
7. Use of the composition according to any one of claims 1-6 in the manufacture of a product for promoting collagen production.
8. Use according to claim 7, characterized in that, The collagen includes type I collagen.
9. Use of the composition according to any one of claims 1-6 in the manufacture of a product for reducing oxidative stress or reducing cell damage.
10. Use of the composition according to any one of claims 1-6 in the manufacture of a product for anti-aging of the skin.